The Europe, Middle East and Africa (EMEA) chronic thromboembolic pulmonary hypertension (CTEPH) registry: Study design and baseline demographics

Creative Commons License

Öngen G., Akdeniz B., Düzenli M. A. , Kültürsay K. H. , Moğulkoç Bıshop N., Mutlu B., ...More

13th PVRI Annual World Congress, Barcelona, Spain, 31 January - 02 February 2019, pp.10

  • Publication Type: Conference Paper / Summary Text
  • City: Barcelona
  • Country: Spain
  • Page Numbers: pp.10



• Pulmonary endarterectomy (PEA) is the treatment of

choice for patients with CTEPH as it is potentially curative.1

However, in non-operable patients or in the presence

of persistent/recurrent CTEPH after surgery, the soluble

guanylate cyclase (sGC) stimulator riociguat is the only

recommended and approved targeted medical treatment

in EMEA countries.1–3

–– Therapies licensed for the treatment of pulmonary arterial

hypertension (PAH) are also often prescribed off-label.4

• While the diagnosis and management of CTEPH have been

assessed in registries in Canada, Western/Central European

countries, and the USA,5–9 there are no available data for

relevant Eastern European and Middle Eastern geographies.

• This CTEPH registry was initiated in Kazakhstan, Lebanon,

Russia, Saudi Arabia, and Turkey in 2016 in order to improve

understanding of the evaluation and management of CTEPH

in these countries. Here, we report the design and baseline

demographics from this registry.